Crescendo Garners Medicare Coverage for Vectra DA
Medicare contractor Palmetto GBA has agreed to reimburse for Crescendo Bioscience's Vectra DA multi-marker molecular diagnostic that assesses rheumatoid arthritis activity.
Vectra DA is a blood-based test that measures the levels of 12 proteins. Doctors can use this test in conjunction with standard clinical to track disease activity in RA patients. With the national coverage agreement between Crescendo and Palmetto, Vectra DA is now a covered benefit for Medicare beneficiaries.